Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide in head and neck cancer: the CONFRONT phase I-II trial
Our results did not achieve the ORR threshold required to reject the null hypothesis in this cohort of unselected patients with relapsed/metastatic head and neck cancer. IL-6 and VEGF were associated with overall survival, whereas TGF-β and IL-4 correlated with irAEs.
Authors
- Nerina Denaro (ORCID: https://orcid.org/0000-0002-8605-4290)
- Ornella Garrone (ORCID: https://orcid.org/0000-0001-7359-5410)
- Marco Merlano (ORCID: https://orcid.org/0000-0002-7944-7467)
- Stefano Bondi (ORCID: https://orcid.org/0000-0002-9163-5540)
- Cristiana Bergamini (ORCID: https://orcid.org/0000-0001-7616-5125)
- Matteo Paccagnella (ORCID: https://orcid.org/0000-0003-2641-9443)
- Danilo Galizia (ORCID: https://orcid.org/0000-0003-4851-5938)
- Lisa Francesca Licitra (ORCID: https://orcid.org/0000-0003-0623-4118)
- Andrea Abbona (ORCID: https://orcid.org/0000-0002-9986-1358)
- Salvatore Alfieri (ORCID: https://orcid.org/0000-0001-8485-2275)
- Ester M. Orlandi (ORCID: https://orcid.org/0000-0001-6495-8574)
- Anna Maria Merlotti (ORCID: https://orcid.org/0000-0002-6412-6660)
Institutions
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Ospedale SS. Annunziata (IT)
- Candiolo Cancer Institute (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104498
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Celgene
- Medpace
- Merck KGaA
- Exelixis
- Daiichi-Sankyo
- Ministero della Salute
- Eisai
- Ipsen